The global Commercial Aquaculture Vaccines market size was estimated to be US$ 272.91 Million in 2022 and is expected to grow at a CAGR of 7.4% between 2023 to 2032.
Commercial Aquaculture Vaccines refer to vaccines that are specifically developed for use in aquaculture to prevent or reduce the incidence of diseases in farmed fish and shellfish. Aquatic diseases can cause significant economic losses for the aquaculture industry, and vaccines are an important tool for disease prevention and management.
Commercial Aquaculture Vaccines are produced using various technologies, including inactivated, live attenuated, subunit, and DNA-based vaccines, and are designed to protect against specific diseases that are common in farmed fish and shellfish. These vaccines are administered to fish and shellfish through various routes, including injection, immersion, and oral administration, depending on the specific vaccine and species.
The use of Commercial Aquaculture Vaccines has become increasingly common in the aquaculture industry as a means of promoting healthier, more sustainable, and more profitable aquaculture operations.
The global commercial aquaculture vaccines market is being driven by several factors. Firstly, the rising prevalence of aquatic diseases, such as bacterial infections and parasitic infections, has led to an increased demand for commercial aquaculture vaccines. Diseases can result in significant losses to the aquaculture industry, highlighting the importance of preventive measures such as vaccination.
Secondly, growing investment in the aquaculture industry, both from governments and private organizations, is leading to increased production of fish and seafood. This increase in production is expected to boost demand for commercial aquaculture vaccines as preventive measures.
Finally, the increasing demand for seafood products, driven by a growing population, changing dietary habits, and rising disposable income, is driving the growth of the aquaculture industry, which in turn is driving the demand for commercial aquaculture vaccines.
These factors are interlinked, and as the demand for seafood products increases, the production of fish and seafood is expected to increase as well, which will lead to a further demand for commercial aquaculture vaccines. This market is expected to continue growing due to favorable government regulations, technological advancements, and increasing consumer awareness of food safety.
Companies operating in this market are expected to invest in research and development to meet the growing demand for effective and safe commercial aquaculture vaccines.
Based on species, the salmon segment is one of the largest segments in the market due to the high demand for farmed salmon and the prevalence of diseases that affect the species. Salmon is one of the most widely farmed species in the world and is known to be susceptible to a range of viral and bacterial diseases, such as Infectious Salmon Anemia (ISA), Salmonid Rickettsial Septicaemia (SRS), and Pancreas Disease (PD), among others.
These diseases can cause significant economic losses for salmon farmers due to mortality, reduced growth rates, and decreased production. Therefore, disease prevention measures such as vaccines are crucial for the sustainable growth of the salmon industry.
Several commercial aquaculture vaccines are available for salmon, including inactivated, live attenuated, and recombinant vaccines. For example, a recombinant vaccine for ISA in salmon was recently developed and is currently in use in Norway, which is one of the largest producers of farmed salmon in the world.
The use of vaccines has helped reduce the incidence of diseases in salmon farms, leading to increased production and profitability. Other species such as tilapia, carp, and catfish are also important segments in the Global Commercial Aquaculture Vaccines Market, and the demand for vaccines for these species is expected to increase as the aquaculture industry continues to grow and expand globally.
Geographically, the global commercial aquaculture vaccines market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America.
Following are some of the major trends in these regions –
North America: The North American market for commercial aquaculture vaccines is driven by the presence of large aquaculture industries in the US and Canada, particularly for species such as salmon, trout, and catfish.
The increasing demand for seafood and the need for disease prevention measures are driving the growth of the market. Additionally, the region has a well-developed regulatory framework for the approval and use of commercial aquaculture vaccines.
Europe: The European market for commercial aquaculture vaccines is driven by the high demand for farmed salmon, trout, and carp. The region has a strong regulatory framework for aquaculture production and is focused on promoting sustainable aquaculture practices.
The increasing focus on animal welfare and environmental sustainability is driving the demand for safe and effective disease prevention measures such as vaccines.
Asia-Pacific: The Asia-Pacific market for commercial aquaculture vaccines is driven by the high demand for seafood products, particularly in countries such as China, India, and Indonesia. The region is also the largest producer of farmed fish and shellfish in the world, and diseases are a significant concern for aquaculture production. The increasing adoption of advanced technologies and the development of new vaccines are driving the growth of the market.
Middle East and Africa: The Middle East and Africa market for commercial aquaculture vaccines is driven by the increasing demand for seafood products and the need to reduce the reliance on wild-capture fisheries. The region has a growing aquaculture industry, particularly for species such as tilapia and catfish, and disease prevention measures such as vaccines are becoming increasingly important for sustainable production.
South America: The South American market for commercial aquaculture vaccines is driven by the large aquaculture industries in countries such as Chile, Brazil, and Ecuador. The increasing demand for farmed salmon and shrimp and the prevalence of diseases that affect these species are driving the growth of the market. Additionally, the region has a favorable regulatory environment for the approval and use of commercial aquaculture vaccines.
The major growth strategies adopted by companies operating in the Global Commercial Aquaculture Vaccines Market include:
Product development and innovation: Companies are investing in research and development to develop new and effective vaccines that can prevent a range of diseases in different species of fish and shellfish.
Strategic partnerships and collaborations: Companies are forming partnerships with other companies, research institutes, and universities to share knowledge and resources, accelerate product development, and expand their market reach.
Geographic expansion: Companies are expanding their operations to new regions, particularly in developing countries with large aquaculture industries, to tap into the growing demand for commercial aquaculture vaccines.
Mergers and acquisitions: Companies are acquiring or merging with other companies to expand their product portfolios, increase their market share, and improve their competitive position.
Marketing and branding: Companies are investing in marketing and branding to increase awareness of their products and build brand loyalty among customers.
AB Vista, AniCon Labor GmbH, Benchmark Holdings Plc, Hipra, Merck & Co., Inc., Nisseiken Co., Ltd., Novartis International AG, Pfizer Inc., PHARMAQ AS, Tecnovax SA, Vaxxinova GmbH, Vetanco, Virbac, Zoetis Inc., Zydus Animal Health and many more.
By Vaccine Type:
By Species:
By Administration:
By Region
The commercial aquaculture vaccines market size was estimated to be US$ 272.91 Million in 2022.
The commercial aquaculture vaccines market is expected grow at a CAGR of 7.4% between 2023 to 2032.
The global commercial aquaculture vaccines market is being driven by the rising prevalence of aquatic diseases, such as bacterial infections and parasitic infections and growing investment in the aquaculture industry, both from governments and private organizations, is leading to increased production of fish and seafood.
The North American market for commercial aquaculture vaccines is driven by the presence of large aquaculture industries in the US and Canada, particularly for species such as salmon, trout, and catfish.
The major growth strategies adopted by these companies are investing in marketing and branding to increase awareness of their products and build brand loyalty among customers.
Based on species, the salmon segment is one of the largest segments in the market due to the high demand for farmed salmon and the prevalence of diseases that affect the species.
AB Vista, AniCon Labor GmbH, Benchmark Holdings Plc, Hipra, Merck & Co., Inc., Nisseiken Co., Ltd., Novartis International AG, Pfizer Inc., PHARMAQ AS, Tecnovax SA, Vaxxinova GmbH, Vetanco, Virbac, Zoetis Inc., Zydus Animal Health KP among others, are the leading players in this market.
Copyright © 2024 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved